Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 8/20 | 0.36 |
| ▸ | CNR1 | P21554 | 6/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | USP1 | O94782 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1950087 | 0.90 | CNR2 (0.37) | CNR2CNR1ALDH1A1GAALMNA | |
| SCHEMBL1951123 | 0.89 | DRD2 (0.37) | CNR2CNR1ALDH1A1GAALMNA | |
| SCHEMBL1948776 | 0.85 | CNR2 (0.40) | CNR2CNR1ALDH1A1GAALMNA | |
| SCHEMBL1949726 | 0.85 | PARP1 (0.43) | CNR2CNR1ALDH1A1GAALMNA | |
| SCHEMBL1949371 | 0.80 | NOTUM (0.47) | ALDH1A1GAALMNAPOLBPKM | |
| SCHEMBL1949299 | 0.80 | CNR2 (0.38) | CNR2CNR1ALDH1A1GAALMNA | |
| SCHEMBL1951397 | 0.79 | CNR2 (0.40) | CNR2CNR1ALDH1A1GAALMNA | |
| SCHEMBL1950702 | 0.79 | NOTUM (0.47) | ALDH1A1GAALMNAPOLB | |
| SCHEMBL1949516 | 0.78 | CNR2 (0.38) | CNR2CNR1ALDH1A1GAALMNA | |
| SCHEMBL2641573 | 0.78 | NOTUM (0.44) | ALDH1A1GAALMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110136859-A1 | Compounds | XENTION LTD. (GB) | 2011-06-09 | — | — | US | claimed |
| US-20110136859-A1 | Compounds | XENTION LTD. (GB) | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136859-A1 | Compounds | CYP2C8, CYP3A7, CYP2A7 | CNR2 97/4885CNR1 16/4885ALDH1A1 1680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.